You are here

MATRIX Trial Bolsters Bivalirudin

Dr. Cindy Grines of the Detroit Medical Center says the MATRIX trial reaffirmed bivalirudin’s safety and effectiveness despite not meeting its primary endpoint. Mortality and bleeding complications were reduced significantly among angioplasty patients receiving bivalirudin versus unfractionated heparin regardless of vascular access site.

American College of Cardiology, March 2015